Valtier S, Cody J T
Clinical Research Squadron, 59th Medical Wing, Lackland AFB, Texas 78236-5319, USA.
J Anal Toxicol. 2000 Oct;24(7):606-13. doi: 10.1093/jat/24.7.606.
Clobenzorex (Asenlix) is an anorectic drug metabolized by the body to amphetamine, thus causing difficulty in the interpretation of amphetamine-positive drug tests. Previous studies have shown the parent drug and several metabolites are excreted in urine. Clobenzorex itself has been detected for as long as 29 h postdose using a detection limit of 1 ng/mL. Despite this fact, several amphetamine-positive samples (> or = 500 ng/mL) contained no detectable clobenzorex. Thus, the absence of clobenzorex in the urine does not exclude the possibility of its use. To more definitively assess the possibility of clobenzorex use, evaluation of another metabolite was considered. One study reported the presence of unidentified hydroxy metabolites of clobenzorex for as long as amphetamine was detected in some subjects. To assess the viability of using a hydroxy metabolite to confirm the use of clobenzorex in samples containing amphetamine, 4-hydroxyclobenzorex was synthesized for this study. This metabolite proved to be easily detected and was typically found at levels higher than amphetamine in amphetamine-positive urines, long after clobenzorex itself was no longer detected. Samples obtained from a controlled single-dose study involving the administration of clobenzorex (30 mg) were analyzed for the presence of the 4-hydroxy metabolite. The analytical procedure used acid hydrolysis followed by liquid-liquid extraction and analysis with gas chromatography-mass spectrometry by monitoring ions at m/z 125, 330, and 364. 4-Hydroxyclobenzorex and its 3-Cl regioisomer were used in the identification and quantitation of the metabolite. Peak concentrations of 4-hydroxyclobenzorex were found at approximately 1:30-5:00 h postdose and ranged from approximately 5705 to 88,410 ng/mL. Most importantly, however, all samples that contained amphetamine at > or = 500 ng/mL also contained detectable amounts of this hydroxy metabolite (LOD 10 ng/mL), making it a valuable tool in differentiating use of clobenzorex from illicit amphetamine use.
氯苄雷司(阿塞利克斯)是一种食欲抑制药物,可被人体代谢为苯丙胺,因此会给苯丙胺阳性药物检测结果的解读带来困难。先前的研究表明,母体药物及其几种代谢物会通过尿液排出。使用1纳克/毫升的检测限,在给药后长达29小时的尿液中都能检测到氯苄雷司本身。尽管如此,一些苯丙胺阳性样本(≥500纳克/毫升)中并未检测到氯苄雷司。因此,尿液中未检测到氯苄雷司并不能排除使用过该药的可能性。为了更确切地评估使用氯苄雷司的可能性,人们考虑对另一种代谢物进行检测。一项研究报告称,在一些受试者中,只要检测到苯丙胺,就能检测到氯苄雷司的未鉴定羟基代谢物。为了评估使用羟基代谢物来确认在含有苯丙胺的样本中是否使用过氯苄雷司的可行性,本研究合成了4-羟基氯苄雷司。这种代谢物很容易被检测到,并且在氯苄雷司本身不再能被检测到很久之后,在苯丙胺阳性尿液中其含量通常高于苯丙胺。对一项涉及服用氯苄雷司(30毫克)的对照单剂量研究中获取的样本进行分析,以检测4-羟基代谢物的存在情况。分析程序采用酸水解,然后进行液-液萃取,并通过监测质荷比为125、330和364的离子,利用气相色谱-质谱联用仪进行分析。4-羟基氯苄雷司及其3-氯区域异构体用于该代谢物的鉴定和定量分析。4-羟基氯苄雷司的峰值浓度在给药后约1:30至5:00小时出现,范围约为5705至88410纳克/毫升。然而,最重要的是,所有苯丙胺含量≥500纳克/毫升的样本中也都含有可检测量的这种羟基代谢物(检测限为10纳克/毫升),这使得它成为区分氯苄雷司使用和非法使用苯丙胺的一种有价值的工具。